John Lachin, ScD

John Lachin is a Professor of Biostatistics and Epidemiology and a Professor of Statistics in the Department of Epidemiology and Biostatistics. He has a joint appointment in the Department of Statistics at the Columbian School of Arts and Sciences.

• Phone: (301) 816-8081
• Fax: (301) 881-3742
• Email: JML@biostat.bsc.gwu.edu

One of the nation's premier experts on statistical and research methodology, Dr. Lachin led the development of GW's graduate program in biostatistics and epidemiology, serving as director of the program from its inception in 1995 until 2004. He is now co-director of The Biostatistics Center, a research facility of the University. Dr. Lachin is a Fellow of the American Statistical Association and the Royal Statistical Society and served in 2002-03 as President of the Society for Clinical Trials. His co-authored book Randomization in Clinical Trials: Theory and Practice (John Wiley & Sons, 2002) won the American Association of Publishers' award for "Outstanding professional and scholarly title of 2002 in mathematics and science." He is also the author of Biostatistical Methods (John Wiley, 2000).

Knowledge about preventing and treating diabetes has taken great strides forward as a result of Dr. Lachin's decades-long involvement with a series of NIH-funded trials. He is currently principal investigator of both the Type 1 Diabetes TrialNet and the study of the Epidemiology of Diabetes Interventions and Complications (EDIC), as well as co-principal investigator for the Diabetes Prevention Program (DPP). In 1994, he was a co-recipient of the American Diabetes Association's Charles H. Best Medal for Distinguished Service in the Cause of Diabetes, which was awarded to the Diabetes Control and Complications Trial (DCCT) Research Group.

Education

Doctor of Science (Biostatistics), University of Pittsburgh, 1972

Teaching

Introduction to Biostatistics, Department of Statistics
Stat 210-Data Analysis, Department of Statistics
PubH 265-Design of Medical Studies, Department of Statistics
PubH 266-Biostatistical Methods, Department of Statistics
Advanced Biostatistical Methods, Department of Statistics
Stat 227-Survival Analysis, Department of Statistics

Research

Dr. Lachin's recent publications have focused on the intent-to-treat principle in clinical trials, sample size evaluation, group sequential methods, analysis of repeated measures and survival analysis. Among the key findings of the EDIC study is that a prior period of intensive therapy to maintain near-normal glycemia in type 1 diabetes reduces the long-term development of atherosclerosis (NEJM, 2002) and progression of diabetic kidney disease (JAMA, 2003). Results from the Diabetes Prevention Program demonstrate that a lifestyle intervention or use of the drug Metformin reduce the risk of developing type 2 diabetes (NEJM, 2002).

Community Service

Professor Lachin serves on the Data and Safety Monitoring Board of numerous clinical trials, including ones sponsored by the National Heart Lung and Blood Institute, the National Institute of Diabetes, Digest and Kidney Diseases and the pharmaceutical industry. He has served on the editorial board of Controlled Clinical Trials and as a board member and committee chairman at the Society for Clinical Trials, prior to assuming the presidency.

Departments

• Epidemiology and Biostatistics

Institutes & Centers

• Biostatistics Center

Research Activities

• Diabetes Control and Complications Trial (DCCT)
• Epidemiology of Diabetes Intervention and Complications (EDIC)
• National Cooperative Gallstone Study
• Statistical Methods in Cancer Clinical Trials (Lachin)
• Study of Plasmapheresis in Severe Lupus Nephritis
• Type 1 Diabetes TrialNet Coordinating Center (TrialNet)

Publications

• C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001
  Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004;53:250-64.
• Group sequential large sample T2-like 2 tests for multivariate observations
  Lachin JM, Greenhouse SW, Bautista OM. Group sequential large sample T2-like 2 tests for multivariate observations. Stats in Med 2003;22:3357-68.
• Over-ruling a group sequential boundary - a stopping rule versus a guideline.
  Lan KKG, Lachin JM, Bautista OM. Over-ruling a group sequential boundary - a stopping rule versus a guideline. Stats in Med 2003;22:3347-55.
• A tribute to Samuel W. Greenhouse.
  Lachin JM. A tribute to Samuel W. Greenhouse. Stats in Med 2003;22:3267-76.
• Corrections for bias in maximum likelihood parameter etimates due to nuisance parameters.
  Hu MX and Lachin JM. Corrections for bias in maximum likelihood parameter etimates due to nuisance parameters. Comm in Stats 2003;32:619-39.
• Randomization in clinical trials: Theory and practice
  Rosenberger W, Lachin JM. Randomization in clinical trials: Theory and practice. John Wiley and Sons; 2002.
• A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.
  Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, Haffner SM, Levy D, Lachin JM, Berry RA, Heise MA, Jones NP, Freed MI. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002;25:1737-43.
• Application of robust estimating equations to the analysis of quantitative longitudinal data
  Hu M and Lachin JM. Application of robust estimating equations to the analysis of quantitative longitudinal data, Stat Med 2001;20:3411-28.
• Sam Greenhouse: 1918-2000.
  Lachin JM and Greenhouse, J. Sam Greenhouse: 1918-2000. Am Stat News 2001 Sept, 4-5, 2001.
• Biostatistical Methods: The assessment of relative risks.
  Lachin JM. Biostatistical Methods: The assessment of relative risks. John Wiley and Sons; 2000.
• A flexible stochastic curtailing procedure for the log-rank test.
  Bautista OM, Bain RP and Lachin JM. A flexible stochastic curtailing procedure for the log-rank test. Control Clin Trials 2000;21:428-39.
• Statistical considerations in the intent-to-treat principle.
  Lachin JM. Statistical considerations in the intent-to-treat principle. Control Clin Trials 2000;21:167-89.
• Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy.
  The DCCT/EDIC Research Group (J. Lachin, Director, Coordinating Center, member, Writing Committee). Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy. JAMA 2003;290: 2159- 67.
• Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus.
  The DCCT/EDIC Research Group (J. Lachin, Director, Coordinating Center, member, Writing Committee). Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. New Engl J Med 2003;348:2294-303.
• The effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus.
  The DCCT/EDIC Research Group (J. Lachin, Director, Coordinating Center, member, Writing Committee). The effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002;287:2563-9.
• The beneficial effects of intensive therapy of diabetes during adolescence: Outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT).
  The DCCT/EDIC Research Group (J. Lachin, Director, Coordinating Center). The beneficial effects of intensive therapy of diabetes during adolescence: Outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr 2001;139:804-12.
• Influence of Intensive Diabetes Treatment on Body Weight and Composition of Adults with Type 1 Diabetes in the Diabetes Control and Complications Trial.
  The Diabetes Control and Complications Trial Research Group (J. Lachin, Director, Coordinating Center). Influence of Intensive Diabetes Treatment on Body Weight and Composition of Adults with Type 1 Diabetes in the Diabetes Control and Complications Trial. Diabetes Care 2001;24:1711-21.
• The effect of pregnancy on microvascular complications in the Diabetes Control and Complications Trial (DCCT).
  The DCCT Research Group (J. Lachin, Director, Coordinating Center; member,Writing Committee). The effect of pregnancy on microvascular complications in the Diabetes Control and Complications Trial (DCCT). Diabetes Care 2000;23:1084-91.
• Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.
  The DCCT/EDIC Research Group (J. Lachin, Director, Coordinating Center; Chair, Writing Committee). Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. New Engl J Med 2000;342:381-9.
• Within trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes.
  The DPP Research Group. (J. Lachin, Co-Director, Coordinating Center, member, Writing Committee). Within trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 2003 Sep;26:2518-23
• Cost associated with the primary prevention of type 2 Diabetes Mellitus in the Diabetes Prevention Program.
  The DPP Research Group (J. Lachin, Co-Director, Coordinating Center, member, Writing Committee). Cost associated with the primary prevention of type 2 Diabetes Mellitus in the Diabetes Prevention Program. Diabetes Care 2003;26:36-47.
• Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program.
  The Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. Diabetes Care 2003;26:977-80.
• The Diabetes Prevention Program: recruitment methods and results.
  The DPP Research Group (J. Lachin, Co-Director, Coordinating Center). The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials, 2002;23:157-71.
• The Diabetes Prevention Program (DPP): Description of lifestyle intervention
  The DPP Research Group (J. Lachin, Co-Director, Coordinating Center). The Diabetes Prevention Program (DPP): Description of lifestyle intervention. Diabetes Care 2002;25: 2165-71.
• Hypertension, Insulin, Proinsulin in participants with impaired glucose tolerance.
  The DPP Research Group (J. Lachin, Co-Director, Coordinating Center, member, Writing Committee). Hypertension, Insulin, Proinsulin in participants with impaired glucose tolerance. Hypertension 2002;40:679-86.
• Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
  The Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
• The Diabetes Prevention Program: baseline characteristics of the randomized cohort.
  The DPP Research Group (J. Lachin, Co-Director, Coordinating Center). The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care 2000;23:1619-29.
• The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes.
  The DPP Research Group (J. Lachin, Co-Director, Coordinating Center). The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care, 1999;22:623-34.
• Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis.
  Najafi CC, Korbet SM, Lewis EJ, Schwartz MM, Reichlin M and Evans J, for the Collaborative Study Group. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int 2001;59:2156-63.
• Factors predictive of outcome in severe lupus nephritis.
  Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, and Rohde RD for the Collaborative Study Group. Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis 2000;35:904-14.